See more : Remedy Entertainment Oyj (RMDEF) Income Statement Analysis – Financial Results
Complete financial analysis of SUDARSHAN PHARMA INDUSTRIES LI (SUDARSHAN.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SUDARSHAN PHARMA INDUSTRIES LI, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- BizConf Telecom Co.,Ltd. (300578.SZ) Income Statement Analysis – Financial Results
- Sata Construction Co., Ltd. (1826.T) Income Statement Analysis – Financial Results
- Revolution Co., Ltd. (8894.T) Income Statement Analysis – Financial Results
- Imagine Lithium Inc. (ILI.V) Income Statement Analysis – Financial Results
- Highwealth Construction Corp. (2542.TW) Income Statement Analysis – Financial Results
Sudarshan Pharma Industries Ltd. (SUDARSHAN.BO)
About Sudarshan Pharma Industries Ltd.
Sudarshan Pharma Industries Ltd. engages in the provision of specialty chemicals, intermediates, and active pharmaceuticals ingredients. The firm outsourced its supplies to provide products to clients in India and abroad. It also involved in contract manufacturing, outsource and supplies of generic pharma formulation, and medicines to healthcare institution, government, NGO, and hospitals. The company was founded on July 23, 2008 and is headquartered in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 4.64B | 4.61B | 3.57B | 1.93B | 1.48B |
| Cost of Revenue | 4.27B | 4.42B | 3.43B | 1.81B | 1.40B |
| Gross Profit | 361.77M | 192.76M | 139.17M | 119.33M | 82.67M |
| Gross Profit Ratio | 7.80% | 4.18% | 3.90% | 6.17% | 5.59% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 146.09M | 50.56M | 37.67M | 55.11M | 32.04M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 146.09M | 50.56M | 37.67M | 55.11M | 32.04M |
| Cost & Expenses | 4.42B | 4.47B | 3.47B | 1.87B | 1.43B |
| Interest Income | 0.00 | 4.90M | 1.99M | 253.00K | 109.00K |
| Interest Expense | 89.45M | 54.02M | 33.79M | 32.25M | 27.23M |
| Depreciation & Amortization | 12.44M | 9.07M | 8.66M | 7.42M | 3.47M |
| EBITDA | 254.17M | 151.27M | 110.17M | 71.64M | 47.86M |
| EBITDA Ratio | 5.48% | 3.28% | 3.09% | 3.71% | 3.66% |
| Operating Income | 215.68M | 142.20M | 101.51M | 64.22M | 50.63M |
| Operating Income Ratio | 4.65% | 3.08% | 2.84% | 3.32% | 3.42% |
| Total Other Income/Expenses | -63.39M | -47.23M | -30.15M | -28.48M | -33.47M |
| Income Before Tax | 152.28M | 94.96M | 71.36M | 35.75M | 17.16M |
| Income Before Tax Ratio | 3.29% | 2.06% | 2.00% | 1.85% | 1.16% |
| Income Tax Expense | 37.73M | 24.60M | 18.87M | 9.03M | 4.41M |
| Net Income | 114.55M | 70.37M | 52.48M | 26.71M | 12.75M |
| Net Income Ratio | 2.47% | 1.53% | 1.47% | 1.38% | 0.86% |
| EPS | 4.76 | 5.48 | 5.46 | 1.12 | 0.53 |
| EPS Diluted | 4.76 | 5.48 | 5.46 | 1.12 | 0.53 |
| Weighted Avg Shares Out | 24.07M | 12.85M | 9.61M | 23.90M | 23.90M |
| Weighted Avg Shares Out (Dil) | 24.07M | 12.85M | 9.61M | 23.90M | 23.90M |
Source: https://incomestatements.info
Category: Stock Reports